Connect to other sites within the UBM Medica Network
FDA Update: Bevacizumab Is Approved for Cervical Cancer
The FDA has approved bevacizumab (Avastin) for treating persistent, recurrent, or metastatic cervical cancer after studies show gains in overall survival.
Already Had Sex? The HPV Vaccine Still Has Value
The optimal time to get the HPV vaccine is before a first sexual encounter. But getting the vaccine after still offers significant protection against cervical dysplasia.
Pelvic Exams Have Value: Does Skipping Them Put Women at Risk?
The American College of Physicians (ACP) recommends against pelvic exams in asymptomatic, nonpregnant, adult women. Some say this is faulty logic. What say you?
Back to Basics: The Well-Woman Visit
Don’t let time constraints and large patient loads prevent you from providing a thorough well-woman visit. Are you covering all the bases?
FDA Panel: HPV Test Can Replace Pap for Cervical Cancer Screening
An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.
Oral Cancer: From First Detection to Disease Spread
Why the USPSTF has declined to recommend regular screening for oral cancer in primary care, and a new biomarker for metastasis in oral squamous cell carcinoma.
Female Providers, Residents More Likely to Order HPV Testing for Low-Risk Women
Female providers were twice as likely as their male counterparts to order HPV testing for low-risk women aged 30 to 65 who had normal Pap smear results.
By clicking Accept, you agree to become a member of the UBM Medica Community.